CAR-T Therapy Market Dynamics and Analysis by 2031
The CAR-T Therapy Market is expected to register a CAGR of 16.2% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report is segmented by Targeted Antigen (CD 19,BCMA,HER2,GD2,CD 20,CD22,CD30,CD33,HER1 and Others). Further, the market is segmented on the basis of Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer and Others). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report CAR-T Therapy Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
CAR-T Therapy Market Segmentation
Targeted Antigen- CD 19
- BCMA
- HER2
- GD2
- CD 20
- CD22
- CD30
- CD33
- HER1 and Others
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Multiple Myeloma
- Glioblastoma
- Sarcoma
- Neuroblastoma
- Acute Myeloid Leukemia
- Breast Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Colorectal Cancer and Others
Strategic Insights
CAR-T Therapy Market Growth Drivers- Incidence of Cancer: According to World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. According to the International Agency of Research on Cancer, in 2040, 30.3 million new cases will be added to the global cancer burden. Chimeric antigen receptor (CAR) T-cell therapies can potentially treat new type of cancer treatment that uses the immune system to fight cancer. CAR T involves genetically engineering T cells to express a chimeric antigen receptor targeting a specific tumor antigen. Thus, the growing burden of cancer is driving the CAR-T therapy market.
- CAR-T approvals: Globally, cell therapies are widely adopted owing to the availability FDA approved products. In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 1 month of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.
- CAR-T cell manufacturing: Latest developments in CAR-T cell manufacturing are efficiency-driven, scalable, and cost-effective. Reduced human error to improve throughput is a result of automation at the stage of cell processing, therefore, having faster production cycles. Modular facilities have the ability to be flexible and scaled rapidly as needed to meet demand without large capital investments.
- Rising Number of CAR T-Cell Therapies in Clinical Trials: The current landscape for CAR T-cell therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain. JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.
- Focus on Safety: Accordingly, ensuring confidence in such novel treatments also requires that improvements be made to the outcomes from CAR-T therapy by focusing on safety. Research is thus conducted on predictive measures, prevention, and management of one of the common side effects associated with CAR-T treatment, CRS. This includes improvement in protocols concerning the selection and monitoring of patients.
- Biomarker Development: Biomarkers for CAR-T therapy research should be regarded as an important factor that tends to improve the aspects of patient selection and treatment outcomes. This approach aids in knowing the effectiveness of CAR-T therapies and bringing in provisions for the adjustment in a timely manner as deemed necessary. The unification of academia, industry, and clinical research is important for helping in advancing the discovery and validation of new biomarkers that bring innovation into the field of CAR-T therapy.
- Growing Investment in CAR-T Therapy: Companies operating in the T: cell therapy market focus on strategic developments such as collaborations, expansions, agreements, and investment, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. In August 2023, Astellas invested US$ 50 million in Poseida’s CAR T-cell therapy. Astellas will have exclusive negotiation and first refusal for licensing P: MUC1C: ALLO
- in solid tumors as part of the agreement. P: MUC1C: ALLO
- is an allogeneic CAR T- cell therapy targeting cancer: specific Mucin
- protein (MUC1: C) forms. It is currently under investigation in an open: label multicentre Phase I clinical trial (NCT05239143) treating multiple epithelial: derived solid tumor indications.
- Emerging Markets: Rising instances of oncology and increasing health expenses further point to huge potential in emerging markets for CAR-T therapy. The Asia-Pacific region and Latin America are also witnessing a high incidence of cancer cases, thus generating demand for advanced treatments like CAR-T. Local collaboration with international pharmaceutical giants helps in adapting CAR-T technologies to the needs of the local markets and conditions. Affordable CAR-T therapies tailor: made for emerging markets can greatly enhance access and adoption among patients.
- Expansion into Solid Tumors: Various approaches are under investigation to overcome this immunosuppressive tumor microenvironment, including the combination of CAR-T with checkpoint inhibitors. Several CAR-T therapies for solid tumors are being evaluated in various clinical trials that are ongoing to determine their efficacy and safety. These will not only identify potential modifications needed to achieve efficacy but also help determine how best to individualize CAR-T therapies by tailoring them to an individual patient's specific tumor profile, improving response rates, and minimizing adverse effects. Such combinations represent huge opportunities for the expansion of CAR-T therapy to include solid tumors.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the CAR-T Therapy Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the CAR-T Therapy Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORKHave a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Players operating in the market are Bristol Myers Squibb, Immunocore Holdings, Legend Biotech, Jenssen Global Services, Gilead Sciences, Bluebird Bio, Novatis AG, and JW Therapeutics
Acute Lymphocytic Leukemia segment, by therapeutic appication, dominated the market in 2023.
North America region dominated the CAR-T therapy market in 2023.
Growing Investment in CAR-T Therapy act as a opportunity for growth of the market in forecast period.
The CAR-T Therapy Market is estimated to witness a CAGR of 16.2% from 202#to 2031
The major factors driving the CAR-T therapy market are:
1. Incidence of Cancer
2.CAR-T approvals
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 CAR-T Cell Therapy Market - By Targeted Antigen
1.3.2 CAR-T Cell Therapy Market - By Therapeutic Application
1.3.3 CAR-T Cell Therapy Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. CAR-T CELL THERAPY MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CAR-T CELL THERAPY MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. CAR-T CELL THERAPY MARKET - GLOBAL MARKET ANALYSIS
6.1. CAR-T CELL THERAPY - GLOBAL MARKET OVERVIEW
6.2. CAR-T CELL THERAPY - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CAR-T CELL THERAPY MARKET - REVENUE AND FORECASTS TO 2028 - TARGETED ANTIGEN
7.1. OVERVIEW
7.2. TARGETED ANTIGEN MARKET FORECASTS AND ANALYSIS
7.3. CD 19
7.3.1. Overview
7.3.2. CD 19 Market Forecast and Analysis
7.4. BCMA
7.4.1. Overview
7.4.2. BCMA Market Forecast and Analysis
7.5. HER2
7.5.1. Overview
7.5.2. HER2 Market Forecast and Analysis
7.6. GD2
7.6.1. Overview
7.6.2. GD2 Market Forecast and Analysis
7.7. CD 20
7.7.1. Overview
7.7.2. CD 20 Market Forecast and Analysis
7.8. CD22
7.8.1. Overview
7.8.2. CD22 Market Forecast and Analysis
7.9. CD30
7.9.1. Overview
7.9.2. CD30 Market Forecast and Analysis
7.10. CD33
7.10.1. Overview
7.10.2. CD33 Market Forecast and Analysis
7.11. HER1 AND OTHERS
7.11.1. Overview
7.11.2. HER1 and Others Market Forecast and Analysis
8. CAR-T CELL THERAPY MARKET - REVENUE AND FORECASTS TO 2028 - THERAPEUTIC APPLICATION
8.1. OVERVIEW
8.2. THERAPEUTIC APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ACUTE LYMPHOCYTIC LEUKEMIA
8.3.1. Overview
8.3.2. Acute Lymphocytic Leukemia Market Forecast and Analysis
8.4. CHRONIC LYMPHOCYTIC LEUKEMIA
8.4.1. Overview
8.4.2. Chronic Lymphocytic Leukemia Market Forecast and Analysis
8.5. DIFFUSE LARGE B-CELL LYMPHOMA
8.5.1. Overview
8.5.2. Diffuse Large B-Cell Lymphoma Market Forecast and Analysis
8.6. FOLLICULAR LYMPHOMA
8.6.1. Overview
8.6.2. Follicular Lymphoma Market Forecast and Analysis
8.7. MULTIPLE MYELOMA
8.7.1. Overview
8.7.2. Multiple Myeloma Market Forecast and Analysis
8.8. GLIOBLASTOMA
8.8.1. Overview
8.8.2. Glioblastoma Market Forecast and Analysis
8.9. SARCOMA
8.9.1. Overview
8.9.2. Sarcoma Market Forecast and Analysis
8.10. NEUROBLASTOMA
8.10.1. Overview
8.10.2. Neuroblastoma Market Forecast and Analysis
8.11. ACUTE MYELOID LEUKEMIA
8.11.1. Overview
8.11.2. Acute Myeloid Leukemia Market Forecast and Analysis
8.12. BREAST CANCER
8.12.1. Overview
8.12.2. Breast Cancer Market Forecast and Analysis
8.13. PANCREATIC CANCER
8.13.1. Overview
8.13.2. Pancreatic Cancer Market Forecast and Analysis
8.14. HEPATOCELLULAR CARCINOMA
8.14.1. Overview
8.14.2. Hepatocellular Carcinoma Market Forecast and Analysis
8.15. COLORECTAL CANCER AND OTHERS
8.15.1. Overview
8.15.2. Colorectal Cancer and Others Market Forecast and Analysis
9. CAR-T CELL THERAPY MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America CAR-T Cell Therapy Market Overview
9.1.2 North America CAR-T Cell Therapy Market Forecasts and Analysis
9.1.3 North America CAR-T Cell Therapy Market Forecasts and Analysis - By Targeted Antigen
9.1.4 North America CAR-T Cell Therapy Market Forecasts and Analysis - By Therapeutic Application
9.1.5 North America CAR-T Cell Therapy Market Forecasts and Analysis - By Countries
9.1.5.1 United States CAR-T Cell Therapy Market
9.1.5.1.1 United States CAR-T Cell Therapy Market by Targeted Antigen
9.1.5.1.2 United States CAR-T Cell Therapy Market by Therapeutic Application
9.1.5.2 Canada CAR-T Cell Therapy Market
9.1.5.2.1 Canada CAR-T Cell Therapy Market by Targeted Antigen
9.1.5.2.2 Canada CAR-T Cell Therapy Market by Therapeutic Application
9.1.5.3 Mexico CAR-T Cell Therapy Market
9.1.5.3.1 Mexico CAR-T Cell Therapy Market by Targeted Antigen
9.1.5.3.2 Mexico CAR-T Cell Therapy Market by Therapeutic Application
9.1.5.4 US CAR-T Cell Therapy Market
9.1.5.4.1 US CAR-T Cell Therapy Market by Targeted Antigen
9.1.5.4.2 US CAR-T Cell Therapy Market by Therapeutic Application
9.2. EUROPE
9.2.1 Europe CAR-T Cell Therapy Market Overview
9.2.2 Europe CAR-T Cell Therapy Market Forecasts and Analysis
9.2.3 Europe CAR-T Cell Therapy Market Forecasts and Analysis - By Targeted Antigen
9.2.4 Europe CAR-T Cell Therapy Market Forecasts and Analysis - By Therapeutic Application
9.2.5 Europe CAR-T Cell Therapy Market Forecasts and Analysis - By Countries
9.2.5.1 Germany CAR-T Cell Therapy Market
9.2.5.1.1 Germany CAR-T Cell Therapy Market by Targeted Antigen
9.2.5.1.2 Germany CAR-T Cell Therapy Market by Therapeutic Application
9.2.5.2 France CAR-T Cell Therapy Market
9.2.5.2.1 France CAR-T Cell Therapy Market by Targeted Antigen
9.2.5.2.2 France CAR-T Cell Therapy Market by Therapeutic Application
9.2.5.3 Italy CAR-T Cell Therapy Market
9.2.5.3.1 Italy CAR-T Cell Therapy Market by Targeted Antigen
9.2.5.3.2 Italy CAR-T Cell Therapy Market by Therapeutic Application
9.2.5.4 Spain CAR-T Cell Therapy Market
9.2.5.4.1 Spain CAR-T Cell Therapy Market by Targeted Antigen
9.2.5.4.2 Spain CAR-T Cell Therapy Market by Therapeutic Application
9.2.5.5 United Kingdom CAR-T Cell Therapy Market
9.2.5.5.1 United Kingdom CAR-T Cell Therapy Market by Targeted Antigen
9.2.5.5.2 United Kingdom CAR-T Cell Therapy Market by Therapeutic Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific CAR-T Cell Therapy Market Overview
9.3.2 Asia-Pacific CAR-T Cell Therapy Market Forecasts and Analysis
9.3.3 Asia-Pacific CAR-T Cell Therapy Market Forecasts and Analysis - By Targeted Antigen
9.3.4 Asia-Pacific CAR-T Cell Therapy Market Forecasts and Analysis - By Therapeutic Application
9.3.5 Asia-Pacific CAR-T Cell Therapy Market Forecasts and Analysis - By Countries
9.3.5.1 Australia CAR-T Cell Therapy Market
9.3.5.1.1 Australia CAR-T Cell Therapy Market by Targeted Antigen
9.3.5.1.2 Australia CAR-T Cell Therapy Market by Therapeutic Application
9.3.5.2 China CAR-T Cell Therapy Market
9.3.5.2.1 China CAR-T Cell Therapy Market by Targeted Antigen
9.3.5.2.2 China CAR-T Cell Therapy Market by Therapeutic Application
9.3.5.3 India CAR-T Cell Therapy Market
9.3.5.3.1 India CAR-T Cell Therapy Market by Targeted Antigen
9.3.5.3.2 India CAR-T Cell Therapy Market by Therapeutic Application
9.3.5.4 Japan CAR-T Cell Therapy Market
9.3.5.4.1 Japan CAR-T Cell Therapy Market by Targeted Antigen
9.3.5.4.2 Japan CAR-T Cell Therapy Market by Therapeutic Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa CAR-T Cell Therapy Market Overview
9.4.2 Middle East and Africa CAR-T Cell Therapy Market Forecasts and Analysis
9.4.3 Middle East and Africa CAR-T Cell Therapy Market Forecasts and Analysis - By Targeted Antigen
9.4.4 Middle East and Africa CAR-T Cell Therapy Market Forecasts and Analysis - By Therapeutic Application
9.4.5 Middle East and Africa CAR-T Cell Therapy Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa CAR-T Cell Therapy Market
9.4.5.1.1 South Africa CAR-T Cell Therapy Market by Targeted Antigen
9.4.5.1.2 South Africa CAR-T Cell Therapy Market by Therapeutic Application
9.4.5.2 Saudi Arabia CAR-T Cell Therapy Market
9.4.5.2.1 Saudi Arabia CAR-T Cell Therapy Market by Targeted Antigen
9.4.5.2.2 Saudi Arabia CAR-T Cell Therapy Market by Therapeutic Application
9.4.5.3 U.A.E CAR-T Cell Therapy Market
9.4.5.3.1 U.A.E CAR-T Cell Therapy Market by Targeted Antigen
9.4.5.3.2 U.A.E CAR-T Cell Therapy Market by Therapeutic Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America CAR-T Cell Therapy Market Overview
9.5.2 South and Central America CAR-T Cell Therapy Market Forecasts and Analysis
9.5.3 South and Central America CAR-T Cell Therapy Market Forecasts and Analysis - By Targeted Antigen
9.5.4 South and Central America CAR-T Cell Therapy Market Forecasts and Analysis - By Therapeutic Application
9.5.5 South and Central America CAR-T Cell Therapy Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil CAR-T Cell Therapy Market
9.5.5.1.1 Brazil CAR-T Cell Therapy Market by Targeted Antigen
9.5.5.1.2 Brazil CAR-T Cell Therapy Market by Therapeutic Application
9.5.5.2 Argentina CAR-T Cell Therapy Market
9.5.5.2.1 Argentina CAR-T Cell Therapy Market by Targeted Antigen
9.5.5.2.2 Argentina CAR-T Cell Therapy Market by Therapeutic Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. CAR-T CELL THERAPY MARKET, KEY COMPANY PROFILES
11.1. NOVARTIS INTERNATIONAL AG
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. KITE PHARMA, INC. (GILEAD SCIENCES, INC.)
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. JUNO THERAPEUTICS
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. BLUEBIRD BIO, INC. (CELGENE CORPORATION)
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. SORRENTO THERAPEUTICS INC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. MUSTANG BIO, INC
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. AURORA BIOPHARMA INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. LEGEND BIOTECH (GENSCRIPT BIOTECH CORPORATION)
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. PFIZER, INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. CARSGEN THERAPEUTICS, LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TE
1. Novartis International AG
2. Kite Pharma, Inc. (Gilead Sciences, Inc.)
3. Juno Therapeutics (Celgene Corporation)
4. Bluebird Bio, Inc. (Celgene Corporation)
5. Sorrento Therapeutics Inc.
6. Mustang Bio, Inc
7. Aurora Biopharma Inc.
8. Legend Biotech (Genscript Biotech Corporation)
9. Pfizer, Inc.
10. CARsgen Therapeutics, Ltd.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.